Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Institut für Atemwegsforschung GmbH UCB |
---|---|
Information provided by: | Institut für Atemwegsforschung GmbH |
ClinicalTrials.gov Identifier: | NCT00355771 |
The purpose of this study is to investigate, whether levocetirizine 5 mg relieves nasal and ocular symptoms of persistent allergic rhinitis and reduces increased airway resistance and sleep impairment due to this condition.
Condition | Intervention | Phase |
---|---|---|
Allergic Rhinitis |
Drug: Levocetirizine Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Placebo Controlled Pilot Study on the Efficacy of Levocetirizine 5 mg in Reducing Symptoms, Airway Resistance, and Sleep Impairment in Patients With Persistent Allergic Rhinitis |
Enrollment: | 100 |
Study Start Date: | June 2006 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Treatment Group 1: Experimental |
Drug: Levocetirizine
Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
|
Treatment Group 2: Placebo Comparator |
Drug: Placebo
1 tablet OD in the morning for 8 weeks
|
Levocetirizine 5 mg is well established as the treatment of seasonal and perennial rhinoconjunctivitis. This study has been designed, to investigate its efficacy in patients suffering from persistent allergic rhinitis as defined by the ARIA (Allergic Rhinitis and its Impact on Asthma) working group of the WHO.
The study is divided in an 8 ± 2 day screening and a 56 ± 3 day treatment phase. During both periods patients keep a diary reporting on the severity of their nasal and ocular complaints, the use of rescue medication (cromoglycate eye drops and nasal spray), other concomitant medication and adverse events. They apply a 0 to 3 point score (0 = no, 1= mild, 2 = moderate, 3 = severe symptoms) to rate nasal obstruction, rhinorrhea, nasal itching, sneezing and ocular symptoms in regard to their experience during the preceding 24 hours. During the treatment period they additionally report the time of intake of study medication and their assessments of their nasal peak inspiratory flow (NPIF). NPIF is measured every evening before symptom scoring and additionally before each intake of rescue nasal spray. A device similar to the peak flow meters employed for monitoring bronchial asthma is used. Before the treatment period in its middle and at its end patients undergo a polysomnography.
Furthermore 2 weeks after the start of treatment and at its end patients and investigators employ a 5-step scale
(1 = very good, 2 = good, 3 = moderate, 4 = poor, 5= not at all effective) to assess the efficacy of the study medication.
Efficacy is to be established by comparison of a levocetirizine and a placebo treated group.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
China, Sichuan | |
Department of ORL, West China Hospital, Sichuan Hospital | |
Chengdu, Sichuan, China, 610041 |
Principal Investigator: | Claus Bachert, MD, PhD | Institut für Atemwegsforschung |
Responsible Party: | Institut für Atemwegsforschung GmbH ( Claus Bachert, MD PhD ) |
Study ID Numbers: | 1-1-2005 |
Study First Received: | July 24, 2006 |
Last Updated: | January 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00355771 History of Changes |
Health Authority: | China: State Food and Drug Administration |
allergic rhinitis histamine antagonist sleep disorder |
Neurotransmitter Agents Otorhinolaryngologic Diseases Sleep Disorders Rhinitis Anti-Allergic Agents Cetirizine Histamine |
Respiratory Tract Diseases Respiratory Tract Infections Histamine Antagonists Levocetirizine Histamine phosphate Histamine H1 Antagonists |
Neurotransmitter Agents Otorhinolaryngologic Diseases Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Histamine Agents Rhinitis Anti-Allergic Agents Cetirizine Pharmacologic Actions |
Nose Diseases Respiratory Tract Diseases Respiratory Tract Infections Histamine Antagonists Levocetirizine Therapeutic Uses Histamine H1 Antagonists Histamine H1 Antagonists, Non-Sedating |